Abstract
Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.
Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.
Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.
CNS & Neurological Disorders - Drug Targets
Title:Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases
Volume: 17 Issue: 9
Author(s): Kin Yen Chia, Khuen Yen Ng, Rhun Yian Koh and Soi Moi Chye*
Affiliation:
- Applied Biomedical Science and Biotechnology, International Medical University, Kuala Lumpur,Malaysia
Keywords: Inflammation reaction, neurodegenerative disease, oxidative stress, single-chain Fv antibodies, pathological, Alzheimer's disease.
Abstract: Background & Objective: Protein misfolding and aggregation have been considered the common pathological hallmarks for a number of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD). These abnormal proteins aggregates damage mitochondria and induce oxidative stress, resulting in neuronal cell death. Prolonged neuronal damage activates microglia and astrocytes, development of inflammation reaction and further promotes neurodegeneration. Thus, elimination of abnormal protein aggregates without eliciting any adverse effects are the main treatment strategies. To overcome this, recent studies have deployed single- chain fragment variable antibodies (scFvs) to target the pathological protein aggregates, such as amyloid-beta (Aβ) peptides, α-synuclein (α-syn) and Huntingtin (Htt). To date scFv has been effective at inhibiting abnormal protein aggregates formation in both in vitro and in vivo model system of AD, PD and HD.
Conclusion: Currently active research is still ongoing to improve the scFv gene delivery technology, to further enhance brain penetration, intracellular stability, solubility and efficacy of scFv intrabody.
Export Options
About this article
Cite this article as:
Chia Yen Kin, Ng Yen Khuen , Koh Yian Rhun and Chye Moi Soi*, Single-chain Fv Antibodies for Targeting Neurodegenerative Diseases, CNS & Neurological Disorders - Drug Targets 2018; 17 (9) . https://dx.doi.org/10.2174/1871527317666180315161626
DOI https://dx.doi.org/10.2174/1871527317666180315161626 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Cytokine Therapeutics: History and Update
Current Pharmaceutical Design Editorial: Computational Chemistry and Synthetic Strategy of the Design of Novel Monoamine Oxidase Inhibitors
Combinatorial Chemistry & High Throughput Screening Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Tacrine-Huperzine A Hybrids (Huprines) A New Class of Highly Potent and Selective Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer Disease
Mini-Reviews in Medicinal Chemistry Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Dihydropyrimidinones Scaffold as a Promising Nucleus for Synthetic Profile and Various Therapeutic Targets: A Review
Current Organic Synthesis Nasal Polyposis: From Pathogenesis to Treatment, An Update
Inflammation & Allergy - Drug Targets (Discontinued) Modulation of Apoptosis: New Opportunities for Drug Discovery to Treat Autoimmune Thyroiditis
Recent Patents on Inflammation & Allergy Drug Discovery Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Prediction of the Affinity of the Newly Synthesised Azapirone Derivatives for 5-HT1A Receptors Based on Artificial Neural Network Analysis of Chromatographic Retention Data and Calculation Chemistry Parameters
Combinatorial Chemistry & High Throughput Screening Immunopathogenesis of Neurodegenerative Diseases: Current Therapeutic Models of Neuroprotection with Special Reference to Natural Products
Current Pharmaceutical Design Evaluation of Adverse Drug Event Information in US Manufacturer Labels
Current Drug Safety The Effects of Age on Precision Pinch Force Control Across Five Days of Practice
Current Aging Science Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Voltage Gated Calcium Channels as Targets for Analgesics
Current Topics in Medicinal Chemistry Statins and Thrombin
Current Drug Targets - Cardiovascular & Hematological Disorders Adolescents with Same Sex Parents: Does it Make a Difference?
Adolescent Psychiatry Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets